3SBio Inc

3SBio Inc is an investment holding company primarily engaged in the biotechnology and drugs industries. The company was originally founded in 1993 in China and since then has expanded its operations into Sri Lanka, the Dominican Republic, and Thailand. Through its various holding companies, 3SBio Inc is involved in research and development, manufacturing, and the distribution of biopharmaceuticals in these regions and across the People’s Republic of China. 3SBio Inc is currently listed on the Hong Kong Stock Exchange (HKEX) under the ticker 1530.HK. As of 2020, the 1530.HK price chart has registered a 22.187bn HKD market capitalisation. This is based off a 52-week stock range of 6.660 HKD to 8.750 HKD. 3SBio Inc manufactures and distributes a wide range of biopharmaceuticals through its various holding companies. This includes a number of drugs for the treatment of breast cancer, anaemia, vomiting, and thrombosis disorders. Recently, it has expanded to engaging in trading, project management and consultation, and technology services. 3SBio Inc has collaboration agreements with companies such as AstraZeneca, Lilly, Tory, Samsung Bioepis, and INV. To add some diversity to your trading portfolio, add the 3SBio Inc stock ticker to your eToro watchlist for all the latest news and information.